Gabriela Rojas-Limache

Gabriela Rojas-Limache

Auto-generated profile, based on publicly available information

Gabriela Rojas-Limache

Humanify Centro de Bienestar Integral, Instituto de Investigación Nutricional - IIN, Lima, Peru

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2024 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
MRMariano Gallo Ruelas
Mariano Gallo Ruelas
GAGiancarlo Alvarado-Gamarra
Giancarlo Alvarado-Gamarra
AAAdolfo Aramburu
Adolfo Aramburu
GDGandy Dolores-Maldonado
Gandy Dolores-Maldonado
KCKaren Cueva
Karen Cueva
CLClaudio F. Lanata
Claudio F. Lanata
Background and purpose Bioavailability studies and observational evidence suggest that heme iron (HI) may have greater impact on iron status indicators compared with non-heme iron (NHI). This systematic review and meta-analysis aimed to review the current evidence on the effect of the administration of HI compared with NHI for improving iron status in non-hospitalized population groups. Methods We searched Pubmed, CENTRAL, Scopus, Web of Science, and LILACS from inception to July 2024. There was no language restriction or exclusion based on age or iron status. Only randomized controlled trials comparing HI with NHI were considered. A random-effects meta-analysis was performed to compare the effect of treatments for iron status indicators and total side effects (including gastrointestinal side effects). We measured the certainty of the evidence (CoE) using GRADE assessment. Results After screening 3097 articles, 13 studies were included. Most of the interventions used HI in low doses combined with NHI. The meta-analysis showed higher hemoglobin increases in children with anemia or low iron stores receiving HI (MD 1.06 g/dL; 95% CI: 0.34; 1.78; CoE: very low). No statistically significant difference between interventions were found for any iron status indicator in the other population subgroups (CoE: very low). Participants receiving HI had a 38% relative risk reduction of total side effects compared to NHI (RR 0.62; 95% CI 0.40; 0.96; CoE: very low). Conclusion The current evidence comparing HI with NHI is very limited, preliminary findings suggest that interventions using HI may result in fewer side effects and may be superior in children with iron deficiency or anemia. However, given the very low certainty of the evidence, these results need further investigation through high-quality clinical trials. Protocol registration CRD42023483157.

7 March 2026 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Open access
MRMariano Gallo Ruelas
Mariano Gallo Ruelas
GGGian Pierre Gomez-Herrera
Gian Pierre Gomez-Herrera
AAAndrea Albornoz-Pinedo
Andrea Albornoz-Pinedo
MRMilton A Romero-Robles
Milton A Romero-Robles
GRGabriela Rojas-Limache
Gabriela Rojas-Limache
JRJuan Pedro Rojas-Armas
Juan Pedro Rojas-Armas
Short-chain fatty acid (SCFA) production by fermented foods is a promising health strategy regarding inflammation and oxidative stress regulation. However, there is uncertainty whether probiotic yogurt (PY) is truly superior to conventional yogurt (CY). This systematic review and meta-analysis aimed to evaluate current evidence on the effect of PY on SCFAs, oxidative stress, and inflammatory biomarkers. A systematic literature search was performed up to December 2025 on PubMed, Scopus, Embase, Web of Science, and LILACS. Only randomized controlled parallel trials and crossover studies were included. A random effects meta-analysis of standardized mean difference (SMD) and mean differences (MD) was performed. A total of 15,326 articles were selected. After full-text review, 33 trials were considered. Pooled analysis showed a statistically significant increase in fecal acetate levels (SMD 0.29; 95% confidence interval [CI]: 0.02; 0.57). No significant differences were found for propionate, butyrate, and total SCFAs when combining parallel and crossover studies. Subgroup analysis revealed significant differences between study designs in acetate and butyrate. No significant differences were found for C-reactive protein (MD -0.61 mg/L; 95% CI: -2.25; 1.03) and oxidative stress biomarkers. In contrast, interleukin-10 showed a significant increase (SMD 0.48; 95% CI: 0.15; 0.80). Current evidence comparing PY with CY is very limited. Preliminary findings suggest increments of clinically uncertain relevance in fecal acetate levels and interleukin-10. However, due to the very low certainty of the evidence, superiority over CY is uncertain. Further trials are needed to standardize follow-up time doses and to address possible effect modification by study design. Registration: PROSPERO registration number: CRD42024534718.

3 December 2024 in Research Square
Verified
Preprint
Open access
PDF file
MRMariano Gallo Ruelas
Mariano Gallo Ruelas
GAGiancarlo Alvarado-Gamarra
Giancarlo Alvarado-Gamarra
AAAdolfo Aramburu
Adolfo Aramburu
GDGandy Dolores-Maldonado
Gandy Dolores-Maldonado
KRKaren Cueva Rodríguez
Karen Cueva Rodríguez
CLClaudio F. Lanata
Claudio F. Lanata
Background and purpose: Bioavailability studies and observational evidence suggest that heme iron (HI) may have greater impact on iron status indicators compared with non-heme iron (NHI). This systematic review and meta-analysis aimed to review the current evidence on the effect of the administration of HI compared with NHI for improving iron status in non-hospitalized population groups. Methods: We searched Pubmed, CENTRAL, Scopus, Web of Science, and LILACS from inception to July 2024. There was no language restriction or exclusion based on age or iron status. Only randomized controlled trials comparing HI with NHI were considered. A random-effects meta-analysis was performed to compare the effect of treatments for iron status indicators and total side effects (including gastrointestinal side effects). We measured the certainty of the evidence (CoE) using GRADE assessment. Results: After screening 3097 articles, 13 studies were included. Most of the interventions used HI in low doses combined with NHI. The meta-analysis showed higher hemoglobin increases in children with anemia or low iron stores receiving HI (MD 1.06 g/dL; 95% CI: 0.34; 1.78; CoE: Very low). No statistically significant difference between interventions were found for any iron status indicator in the other population subgroups(CoE: Very low). Participants receiving HI had a 38% relative risk reduction of total side effects compared to NHI (RR 0.62; 95% CI 0.40; 0.96; CoE: Very low). Conclusion: The current evidence comparing HI with NHI is very limited, preliminary findings suggest that interventions using HI may result in fewer side effects and may be superior in children with iron deficiency. However, given the very low certainty of the evidence, these results need further investigation through high-quality clinical trials.